Abvc Biopharma (ABVC) Operating Income (2010 - 2026)

Abvc Biopharma (ABVC) has reported Operating Income for 16 consecutive years, with -$779526.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income rose 66.03% year-over-year to -$779526.0; the trailing twelve-month figure through Jun 2026 stood at -$6.5 million (down 63.09% YoY), and the FY2025 full-year result was -$7.2 million, down 51.98% from the prior year.
• Operating Income grew to -$779526.0 in Q2 2026 per ABVC's latest filing, from -$1.6 million in the prior quarter.
• Across five years, Operating Income topped out at -$302316.0 in Q3 2024 and bottomed at -$6.2 million in Q1 2022.
• Historically, Operating Income has averaged -$2.0 million across 5 years, with a median of -$2.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Operating Income surged 85.97% in 2024, then slumped 549.77% in 2025.
• Over 5 years, Operating Income stood at -$3.1 million in 2022, then jumped by 83.66% to -$511835.0 in 2023, then sank by 37.65% to -$704564.0 in 2024, then tumbled by 212.1% to -$2.2 million in 2025, then jumped by 64.55% to -$779526.0 in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$779526.0, -$1.6 million, and -$2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.